A 12-week, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CEP-10953 (150 mg) as treatment for adults with residual excessive sleepiness
- Wilson Rajaratnam, Shanthakumar (Primary Chief Investigator (PCI))
- Kulkarni, Jayashri (Chief Investigator (CI))
- Redman, Jennifer, (Chief Investigator (CI))
Project: Research